ESSA Pharma (EPIX) Competitors

Atyr PHARMA (NASDAQ:ATYR) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Is ATYR or EPIX more profitable?

ESSA Pharma's return on equity of -24.61% beat Atyr PHARMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
ESSA Pharma	N/A	-24.61%	-23.87%

Do analysts prefer ATYR or EPIX?

Atyr PHARMA currently has a consensus price target of $18.60, suggesting a potential upside of 396.00%. ESSA Pharma has a consensus price target of $2.00, suggesting a potential upside of 20.48%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, research analysts plainly believe Atyr PHARMA is more favorable than ESSA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
ESSA Pharma	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk and volatility, ATYR or EPIX?

Atyr PHARMA has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Does the media prefer ATYR or EPIX?

In the previous week, Atyr PHARMA had 6 more articles in the media than ESSA Pharma. MarketBeat recorded 10 mentions for Atyr PHARMA and 4 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 1.63 beat Atyr PHARMA's score of 0.81 indicating that ESSA Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atyr PHARMA	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ESSA Pharma	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals & insiders have more ownership in ATYR or EPIX?

61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by company insiders. Comparatively, 15.5% of ESSA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor ATYR or EPIX?

ESSA Pharma received 335 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 75.87% of users gave ESSA Pharma an outperform vote.

Company	Underperform	Outperform
Atyr PHARMA	Outperform Votes 14 100.00%	Underperform Votes No Votes
ESSA Pharma	Outperform Votes 349 75.87%	Underperform Votes 111 24.13%

Which has higher valuation and earnings, ATYR or EPIX?

ESSA Pharma has lower revenue, but higher earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$235K	1,420.28	-$50.39M	-$0.81	-4.63
ESSA Pharma	N/A	N/A	-$28.54M	-$0.63	-2.63

Summary

ESSA Pharma beats Atyr PHARMA on 10 of the 17 factors compared between the two stocks.